Global Polio Eradication Initiative

Call for Expressions of Interest (EoI)
Developing Sabin-Inactivated Polio Vaccine (sIPV)

The World Health Organization’s Global Polio Eradication Initiative (WHO/POL) is looking for Expressions of Interest from private or public sector vaccine manufacturers in developing countries1 interested in collaborating with WHO and Intravacc in the development, manufacture and distribution of a safe effective and affordable Sabin Inactivated Polio Vaccine (sIPV), that can be produced securely in developing country settings.

Further to Resolution WHA 61.1, directing WHO to develop safer processes for the production of inactivated poliovirus vaccine and affordable strategies for its use in developing countries, WHO is collaborating with Intravacc in the implementation of a project which is aimed at:

- Developing a safe and effective Sabin-IPV for the vaccination of humans against polio, including the establishment of a technology platform, compiling all necessary quality control tests for sIPV, standard operating procedures and documentation, and evaluating the safety and immunogenicity of a candidate vaccine; and
- Transferring that technology to developing country vaccine manufacturers capable of securely producing sIPV.

Pursuant to this collaboration, Intravacc has so far produced clinical lots of sIPV under Good Manufacturing Practices (GMP), established the technology platform, compiled all necessary quality control tests for sIPV and conducted a pre-clinical study on toxicity. Intravacc has also compiled standard operating procedures and other documentation needed for the transfer of technology related to the production and quality control of sIPV. Intravacc has completed phase I studies in adults in Poland and in Cuba, and phase IIa studies in infants in Poland and is working on further optimizing its production process.

Following a first, second and third call for Expressions of Interest in 20102, 20113 and 20124, respectively, WHO, in consultation with Intravacc, is calling for a fourth round of Expressions of Interest from private or public sector vaccine manufacturers in developing countries interested in collaborating with WHO and Intravacc in the development, manufacture and distribution of safe, effective and affordable sIPV targeted to and appropriate for public sector use in developing countries.

---

1 Developing country means any country classified or listed as such by the United Nations, i.e. any country other than Andorra, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Japan, Luxembourg, Monaco, the Netherlands, New Zealand, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, the United Kingdom, and the United States of America, it being understood that the status of any republic, previously included in the former Union of the Soviet Socialist Republics and the former Federal Socialist Republic of Yugoslavia, as well as Albania, Bulgaria, the Czech Republic, Hungary, Poland, Romania, and the Slovak Republic, shall be determined by the first document emanating from the United Nations system classifying or listing it as either a developed, a developing, or least developed country. Republics classified or listed in such document as a developing or least developed country shall be deemed as a developing country.

2 A first call for EoI for Developing Sabin-Inactivated Polio Vaccine was issued on 1 June 2010 and resulted in the selection of two manufacturers for technology transfer.

3 A second call for Expressions of Interest for Developing Sabin-Inactivated Polio Vaccine was issued on 7 July 2011 and resulted in the selection of a further two manufacturers for technology transfer.

4 A third call for EoI for Developing Sabin-Inactivated Polio Vaccine was issued on 27 April 2012 and resulted in the selection of two manufacturers for technology transfer.
In this respect it is intended that Intravacc enters into bilateral technology transfer agreements with selected manufacturers, and provide training, capacity-building and assistance to such manufacturers for the in-country registration of sIPV for the vaccination of humans against polio. Any transfer of technology as aforesaid will be subject to the condition that: (1) the developing country manufacturers concerned have and continue to have the capability to produce securely\(^5\) the licensed sIPV; and that: (2) Intravacc may require each such manufacturer:

(i) to pay Intravacc a modest compensation for the use of any pre-existing proprietary know-how of Intravacc incorporated in the license; and

(ii) to reimburse Intravacc for any costs, reasonably incurred by Intravacc in actually transferring technology (it being understood that Intravacc shall make every effort to limit such costs to the greatest extent possible).

With the exception of any pre-existing know-how of Intravacc incorporated in the licensed method, the licensed method will be free of any applicable industrial property rights and will not necessitate the granting of licenses relating to proprietary know-how and information for the manufacture, use and distribution of the sIPV.

Subject to the above and as otherwise agreed by WHO and Intravacc, the terms and conditions of the bilateral technology transfer agreements will be negotiated in good faith between the selected manufacturers and Intravacc. In the event Intravacc and a selected manufacturer fail to conclude a bilateral technology transfer agreement as aforesaid within a period of twelve months from the date of final selection of the manufacturer in question, WHO may at its sole discretion decide to cancel the selection of that manufacturer.

WHO will provide technical advice and assistance to the selected manufacturers in the development work and in collaboration with the relevant national regulatory authorities, be responsible for monitoring continued compliance by these manufacturers with requirements for secure production.

Interested private or public sector vaccine manufacturers must meet following “minimum criteria”:

a) be located in a developing country;

b) have or be capable of readily acquiring in-house know-how on virus processing techniques, and have or be capable of readily investing in all utilities, facilities and other requirements needed for clinical development and large scale production of sIPV;

c) be committed to collaborating with WHO and Intravacc in a manner consistent with the principles of WHO’s global access strategy for sIPV;

d) agree to comply with and meet all current and future guidelines to produce sIPV securely, including the Global Action Plan (GAP) III requirements, in particular Annex IV (“Biorisk management standard for essential poliovirus facilities”\(^6\)).

e) from the date of conclusion of the bilateral technology transfer agreement with Intravacc, undertake to diligently produce clinical lots, initiate clinical trials within a period of 24 months, and use all reasonable efforts to apply for registration of the product in the country in which they are established within a period of 48 months;

f) have the capability to supply, or be able to readily make arrangements for the supply of, sIPV products to the public sector of developing countries in sufficient quantities to make a meaningful contribution to meeting global demand (e.g. at least 20 million doses annually);

---

\(^5\) “produce securely” means production which after global OPV cessation meets the current requirements for post-eradication IPV production, as published in the WHO Technical Report Series, no 926, 2004 – “Guidelines for safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses”. This definition of “produced securely” will be supplemented by any and all future updates and revisions of the aforesaid Guidelines, WHO’s Biorisk management standard for essential poliovirus facilities and any and all updates and revisions thereof, as well as any future editions, updates and revisions of the WHO Global Action Plan for Laboratory Containment of Wild Polioviruses.

g) agree to supply, or make arrangements for the supply of, sIPV products to the public sector of developing countries at a preferential and affordable price.

Interested parties should also:

1. preferably:
   a) produce vaccine products that are regulated by one or more National Regulatory Authorities (NRAs) which have been assessed by WHO as functional; and
   b) have experience in manufacturing cell-culture derived vaccines, preferably OPV produced from viral seed strains;

2. ideally:
   a) manufacture at least one WHO pre-qualified vaccine product, i.e. in particular pentavalent (DTP-Hib-HepB) product or OPV (either produced from viral seed or filled from supplied prequalified bulk);
   b) have supplied prequalified product(s) to UNICEF and/or other UN procurement agencies in 2013-2015;
   c) agree and be ready to allow for the technology transfer process to be initiated within 12 months after the nomination (e.g., training of production and QC staff, at small scale);
   d) agree to develop both sIPV-combination and sIPV standalone products; and
   e) agree to collaborate with WHO and Intravacc in the conduct of possible future research, if necessary (e.g., product optimization, manufacturing process improvement).

All expressions of interest should include information and supporting documentation on:

- The status, structure, main activities and location of the entity;
- CVs of key staff who would be responsible for the project;
- A copy of the entity’s annual accounts over the last 5 years;
- Other records demonstrating the entity’s sound financial standing;
- A list of the vaccine products licensed by one or more NRA(s), which have been assessed by WHO as functional;
- A list of cell-culture derived vaccine products manufactured by the entity (including those in development);
- A list of WHO pre-qualified products that are currently supplied to UN procurement agencies;
- An overview of: (i) WHO pre-qualified products which the entity has in the past supplied to UNICEF and/or other UN procurement agencies; and of (ii) other products, which the entity has in the past supplied to developing country markets
- Availability of suitable facilities to conduct large scale vaccine production;
- A checklist as per the attached format to demonstrate sufficient in-house technical expertise to securely produce and control sIPV;
- A commitment that the entity will from the date of conclusion of the bilateral technology transfer agreement with Intravacc, undertake to diligently produce clinical lots, initiate clinical trials within a period of 24 months, and use all reasonable efforts to apply for registration of the product in the country in which it is established within a period of 48 months;
- A commitment to comply with and meet all current and future guidelines to produce IPV securely, including GAP III requirements, in particular Annex IV (“Biorisk management standard for essential poliovirus facilities”)8

---

8 See http://www.who.int/immunization_standards/national_regulatory_authorities%20/offices/en/index.html
A statement to indicate the entity’s understanding of, and willingness to collaborating with WHO and Intravacc in accordance with, the principles of WHO's global access strategy for sIPV, specifically by agreeing to:

a) Develop vaccine targeted to and appropriate for public sector use in low- and middle-income developing countries
b) Publish and disseminate the results arising out of the development work in consultation with WHO and without prejudice to any proprietary rights
c) Grant WHO and any interested manufacturers in developing countries so designated by WHO, an irrevocable, non-exclusive, royalty-free, worldwide, license to any results which have not been so published or otherwise released in the public domain
d) Support-on reasonable terms subsequent transfer of the sIPV technology generated through this collaboration to other suitable manufacturers in developing countries so designated by WHO
e) Make the vaccine available, or make arrangements for the availability of the vaccine, to the public sector of developing countries: (i) in sufficient quantities to make a meaningful contribution to meeting global demand (e.g., at least 20 million doses annually); and (ii) at a preferential and affordable price

All other information and documentation that may be needed to demonstrate responsiveness to the requirements of this Call for Expressions of Interest

Manufacturers, which have submitted an EoI in response to the previous three Calls for Expressions of Interest, should submit all required information and documentation again, with a cover letter highlighting any changes from their responses to the previous Call(s).

On the basis of the Expressions of Interest received by it, WHO intends to invite selected candidates to submit a more detailed “business plan”, for consideration by WHO. This business plan will need to include timelines for the sIPV development work, a detailed development plan of standalone and combination sIPV products, and a plan to share the technology with other manufacturers (More details will be communicated to those who will be invited to submit such a detailed business plan). WHO may also invite selected manufacturers for further discussions and/or to submit further information and documentation.

Subject to the terms of this Call for Expressions of Interest, WHO intends to select (in its sole discretion) two manufacturers for technology transfer to take place in 2016.

To promote wide geographical distribution and availability of sIPV, WHO aims to select one or two manufacturers from different countries, preferably in two different regions. Interested entities are invited to submit their expressions of interest to WHO by 29 April 2016 at the latest, addressed as indicated in the box below.

Any information considered by interested entities as confidential must be clearly marked as "confidential".

Incomplete expressions of interest and expressions of interest submitted after the deadline will, in principle, be disregarded (unless WHO, in its sole discretion, decides otherwise in respect of any such incomplete or late application).

WHO reserves the right to freely decide on the selection of those entities who will be invited for further discussions and/or for the submission of a more detailed business plan, in WHO’s sole discretion, and without having to provide any justification to entities who will not be so invited. WHO further reserves the right not to follow up on any expression of interest at all.
WHO may request interested entities to submit further information and documentation. Any request for further information and documentation and any invitation for further discussions and/or for the submission of a more detailed business plan will be exploratory only, to evaluate the merits of a possible collaboration. Such discussions may be subject to appropriate safeguards of confidentiality.

WHO will advise all entities who have submitted an expression of interest whether or not they will be invited for further discussions and/or for the submission of a more detailed business plan. However, no explanation for the selection or rejection of any expression of interest will be provided, and the selection process will not be subject to any claims or appeal. WHO will not in any circumstances reimburse any costs or expenses associated with the submission of an expression of interest (including possible complementary information and documentation), nor any costs associated with possible further discussions and/or the possible submission of a more detailed business plan. The submission and selection process set forth in this document will not be subject to claims for financial compensation of any kind whatsoever.

Finally, it should be noted that although WHO welcomes collaboration with industry in the interest of promoting public health, WHO does not endorse any specific companies or branded products over others. In this regard, the WHO name and emblem may not be used for commercial or promotional purposes.

As noted above, the deadline for the receipt of applications is 29 April 2016.

EXPRESSIONS OF INTEREST SHOULD BE SUBMITTED VIA E-MAIL AND COURIER MAIL TO:

Dr. HIROMASA OKAYASU
POLIO ERADICATION INITIATIVE
WORLD HEALTH ORGANIZATION,
20 AVENUE APPIA
1211 GENEVA 27
SWITZERLAND

EMAIL: polioresearch@who.int

And also visit the website http://www.polioeradication.org/
## Appendix: Checklist for technical expertise

<table>
<thead>
<tr>
<th>Processing techniques</th>
<th>Experience with processing techniques</th>
<th>Processing technique available for sIPV project</th>
<th>Remarks⁹</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Techniques readily available</td>
<td>If techniques not available, willing to invest?</td>
<td>Funding available</td>
</tr>
<tr>
<td></td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
</tr>
<tr>
<td>Cell cultivation on micro-carriers and harvesting</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
</tr>
<tr>
<td>Virus cultivation</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
</tr>
<tr>
<td>Clarification of virus containing medium</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
</tr>
<tr>
<td>Concentration techniques i.e. ultrafiltration</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
</tr>
</tbody>
</table>

⁹ Please clarify the experience and available capability (lab scale or production scale, research or commercial purposes; products involved; used techniques etc.)

Company:
Date:
Names, designation:
Signature:
<table>
<thead>
<tr>
<th>Processing techniques</th>
<th>Experience with processing techniques</th>
<th>Processing technique available for sIPV project</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Techniques readily available</td>
<td>If techniques not available, willing to invest?</td>
<td>Funding available</td>
</tr>
<tr>
<td>Size exclusion chromatography</td>
<td>Yes □  No □</td>
<td>Yes □  No □</td>
<td>Yes □  No □</td>
</tr>
<tr>
<td>Ion exchange chromatography</td>
<td>Yes □  No □</td>
<td>Yes □  No □</td>
<td>Yes □  No □</td>
</tr>
<tr>
<td>Inactivation</td>
<td>Yes □  No □</td>
<td>Yes □  No □</td>
<td>Yes □  No □</td>
</tr>
<tr>
<td>Sterile filtration and filter testing</td>
<td>Yes □  No □</td>
<td>Yes □  No □</td>
<td>Yes □  No □</td>
</tr>
<tr>
<td>Formulation and aseptic final product filling</td>
<td>Yes □  No □</td>
<td>Yes □  No □</td>
<td>Yes □  No □</td>
</tr>
</tbody>
</table>

Please clarify the experience and available capability (lab scale or production scale, research or commercial purposes; products involved; used techniques etc.)

Company: 
Date: 
Names, designation: 
Signature:
<table>
<thead>
<tr>
<th>Quality control tests</th>
<th>Experience with quality control tests</th>
<th>Testing capacity available for sIPV project</th>
<th>Remarks(^{11})</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Techniques readily available</td>
<td>If techniques not available, willing to invest?</td>
</tr>
<tr>
<td>Animal testing (potency of vaccines)</td>
<td>Yes □ No □</td>
<td>Yes □ No □</td>
<td>Yes □ No □</td>
</tr>
<tr>
<td>Neurovirulence testing (safety of vaccines)</td>
<td>Yes □ No □</td>
<td>Yes □ No □</td>
<td>Yes □ No □</td>
</tr>
<tr>
<td>ELISA techniques</td>
<td>Yes □ No □</td>
<td>Yes □ No □</td>
<td>Yes □ No □</td>
</tr>
<tr>
<td>Inactivation testing</td>
<td>Yes □ No □</td>
<td>Yes □ No □</td>
<td>Yes □ No □</td>
</tr>
</tbody>
</table>

\(^{11}\) Please clarify the experience and available capability (lab scale or production scale, research or commercial purposes; products involved; used techniques etc.)

Company:
Date:
Names, designation:
Signature:
| Utilities and facilities requirements | Experience with utilities and facilities | Utility and facility available for siPV project | Remarks  
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HVAC</td>
<td>Utilities readily available</td>
<td>If utilities not available, willing to invest?</td>
<td>Funding available</td>
</tr>
<tr>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
</tr>
<tr>
<td>Autoclaving (both for sterilization and destruction)</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
</tr>
<tr>
<td>WFI system</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
</tr>
<tr>
<td>Clean steam system</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
</tr>
<tr>
<td>Kill tank</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
</tr>
<tr>
<td>Biosafety level (2 or 3)</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
<td>Yes □ No ☐</td>
</tr>
</tbody>
</table>

Please clarify the experience and available capability (lab scale or production scale, research or commercial purposes; products involved; used techniques etc.)

Company:
Date:
Names, designation:
Signature:
### Other requirements

<table>
<thead>
<tr>
<th>Experience with requirements</th>
<th>Capacity for sIPV project</th>
<th>Remarks&lt;sup&gt;13&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Capacity readily available</td>
<td>If capacity not available, willing to invest?</td>
</tr>
<tr>
<td>QA</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
</tr>
<tr>
<td>Is there a general quality assurance system in place at your facility?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GMP</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
</tr>
<tr>
<td>Is there a GMP system in place?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validation</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
</tr>
<tr>
<td>To what extent do you have experience with the validation of equipment, utilities and processes?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical trial expertise</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
</tr>
<tr>
<td>Phase I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post marketing surveillance</td>
<td>Yes ☐ No ☐</td>
<td>Yes ☐ No ☐</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>13</sup> Please clarify the experience and available capability (lab scale or production scale, research or commercial purposes; products involved; used techniques etc.)

*Company:
*Date:
*Names, designation:
*Signature: